Inspira Regains Compliance with Nasdaq Minimum Bid Price Requirement
July 18, 2025
RA'ANANA, Israel, July 18, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has received formal notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), concerning the minimum bid price requirement.
The notice, dated July 17, 2025, stated that for the 10 consecutive business days from July 2, 2025, through July 16, 2025, the closing bid price of the Company's common shares was at or above $1.00 per share. As a result, Inspira has satisfied the requirements for continued listing on the Nasdaq Capital Market, and the matter is now closed. “This compliance milestone is a direct reflection of the market's growing confidence in our strategic trajectory,” said Dagi Ben-Noon, CEO of Inspira Technologies. “The past few weeks have marked a transformative shift for Inspira, from securing a large commercial order to building a pathway with a government partner for national adoption and global scale up. We are not just evolving; we are transforming into something new, significant, and in a class of its own. We are now fully focused on global distribution, execution, and delivering long-term value to our shareholders.”
Inspira is advancing its government-focused strategy following the successful conclusion of high-level talks, building upon a sequence of foundational milestones. These include the clinical integration of the ART100 in Tier-1 U.S. hospitals, the recent expansion of manufacturing capabilities, and the recently announced $22.5 million purchase order. Collectively, these achievements now serve as a powerful catalyst, accelerating Inspira's ongoing discussions with commercial and governmental entities worldwide.
About Inspira Technologies Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company’s U.S. Food and Drug Administration -cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500 — a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. The Company’s recent internal shifts may reflect broader alignment with long-term industry trends, including consolidation, cross-sector collaboration, and potential strategic partnerships. For more information, visit: https://inspira-technologies.com
Market Data 
Markets 
AI
